Chronic Kidney Disease Explained: What eGFR, Albuminuria, and Kidney Risk Actually Mean

Educational disclaimer: This article provides general health education based on published clinical guidelines. It is not medical advice and cannot diagnose, prescribe, or replace a consultation with a qualified clinician. If you have concerns about your kidney health, speak with your doctor.

The kidneys filter blood, regulate fluid and electrolyte balance, and produce hormones. Chronic kidney disease develops when this function declines progressively over months or years.

What Chronic Kidney Disease Means

Chronic kidney disease (CKD) is a long-term condition in which the kidneys gradually lose their ability to filter waste products, excess fluid, and electrolytes from the blood. It is defined clinically as abnormalities of kidney structure or function that persist for more than three months.

Your kidneys perform several critical functions:

• Filtering approximately 180 litres of blood per day, removing waste products as urine
• Regulating fluid balance, electrolytes (sodium, potassium, calcium, phosphorus), and acid-base status
• Producing erythropoietin, a hormone that stimulates red blood cell production
• Activating vitamin D for bone and calcium metabolism
• Helping regulate blood pressure through the renin-angiotensin system

CKD affects roughly 10% of adults worldwide, yet most people with early-stage disease are unaware of it because symptoms typically do not appear until kidney function has declined substantially.

How Kidney Function Is Measured

Estimated Glomerular Filtration Rate (eGFR)

eGFR is the primary measure used to estimate how well your kidneys are filtering. It is calculated from a blood test (serum creatinine or cystatin C) combined with age and sex, and is expressed in mL/min/1.73 m².

A normal eGFR is generally above 90 mL/min/1.73 m². Lower values indicate reduced kidney function, though a single reading must be interpreted in clinical context.

Important limitations of eGFR:

• eGFR is an estimate, not a direct measurement of kidney function.
• It can be affected by muscle mass, diet (high protein intake), hydration status, and certain medications.
• A single eGFR reading may not reflect true kidney function — trends over time are more informative.
• The 2021 CKD-EPI equation (recommended by NKF-ASN) removed the race variable, but population-level differences in creatinine generation still exist.
• Cystatin C-based or combined equations may be more accurate in some individuals.

Albuminuria (Urine Albumin-to-Creatinine Ratio)

Albuminuria — the presence of the protein albumin in urine — is an independent marker of kidney damage and cardiovascular risk. It is measured using the urine albumin-to-creatinine ratio (UACR) from a spot urine sample.

Even moderately increased albuminuria (A2) signals kidney damage and elevated cardiovascular risk, often before eGFR declines.

CKD Staging

CKD is staged using both eGFR and albuminuria together:

The combination of GFR stage and albuminuria category determines overall risk and guides monitoring frequency. Higher albuminuria at any GFR stage indicates greater risk of progression and cardiovascular events.

Why CKD Can Cause Harm

CKD is often called a "silent" condition because it typically produces no symptoms in early stages. By the time symptoms appear, significant kidney function has usually been lost. The harm from CKD operates through several mechanisms:

• Cardiovascular risk amplification — CKD independently increases the risk of heart attack, stroke, and heart failure at every stage. People with CKD are statistically more likely to die from cardiovascular disease than to progress to dialysis.
• Fluid and electrolyte imbalance — as filtration declines, the kidneys struggle to maintain normal sodium, potassium, calcium, and phosphorus levels, and to excrete excess fluid.
• Anaemia — reduced erythropoietin production leads to fewer red blood cells, causing fatigue and reduced exercise tolerance.
• Bone and mineral disorder (CKD-MBD) — disrupted calcium, phosphorus, and vitamin D metabolism weakens bones and can cause vascular calcification.
• Metabolic acidosis — impaired acid excretion can accelerate muscle wasting and bone loss.
• Progression to kidney failure — without intervention, CKD can progress to end-stage kidney disease (ESKD) requiring dialysis or transplantation.

The Diabetes–Hypertension–CKD–Cardiovascular Connection

CKD does not exist in isolation. It shares causes, consequences, and risk amplifiers with diabetes, hypertension, and cardiovascular disease:

• Diabetes is the leading cause of CKD globally. Sustained high blood sugar damages the small blood vessels in the kidneys (diabetic nephropathy), progressively impairing filtration.
• Hypertension is both a cause and a consequence of CKD. High blood pressure damages kidney blood vessels, and damaged kidneys lose the ability to regulate blood pressure effectively — creating a vicious cycle.
• CKD accelerates atherosclerosis. Reduced kidney function promotes inflammation, oxidative stress, and vascular calcification that compound traditional cardiovascular risk factors.
• Cardiorenal syndrome describes the bidirectional relationship: heart failure impairs kidney perfusion, and kidney failure causes fluid overload that strains the heart.

This interconnection is why clinical guidelines recommend routine kidney function screening (eGFR and UACR) for everyone with diabetes, hypertension, or established cardiovascular disease.

Who Is At Higher Risk

Major Risk Factors

• Diabetes (type 1 or type 2) — the single largest cause of CKD.
• Hypertension — the second most common cause.
• Cardiovascular disease — heart failure, coronary artery disease, and peripheral vascular disease.
• Family history of kidney disease
• Age over 60 — kidney function naturally declines with age.
• Obesity — associated with glomerular hyperfiltration and accelerated kidney damage.

Additional Risk Factors

• Certain ethnicities — Black, Hispanic, Indigenous, and some Asian populations have higher CKD prevalence.
• Smoking — accelerates kidney function decline.
• Recurrent kidney stones or urinary tract infections
• Nephrotoxic medications — regular use of NSAIDs (ibuprofen, naproxen), certain antibiotics, and contrast dyes can damage kidneys over time.
• Autoimmune conditions — lupus, IgA nephropathy, and other glomerular diseases.
• Low birth weight — associated with fewer nephrons and higher lifetime CKD risk.

What Usually Helps Reduce Risk

These are population-level approaches supported by clinical evidence. Discuss what is appropriate for your situation with your clinician.

• Blood pressure management — keeping blood pressure within target ranges is the single most important modifiable factor for slowing CKD progression.
• Blood sugar management — in people with diabetes, maintaining glycaemic targets reduces the risk and progression of diabetic kidney disease.
• Not smoking — smoking cessation slows kidney function decline and reduces cardiovascular risk.
• Sodium reduction — limiting sodium intake (generally <2 g/day) helps control blood pressure and reduce proteinuria.
• Adequate hydration — drinking enough water supports kidney function, but excessive fluid intake is not beneficial and may be harmful in advanced CKD.
• Limiting nephrotoxic exposures — avoiding regular NSAID use and unnecessary contrast dye exposure where possible.
• Physical activity — regular moderate exercise improves cardiovascular fitness and metabolic health in people with CKD.
• Maintaining a healthy weight — reducing obesity-related glomerular hyperfiltration.

Dietary protein and potassium/phosphorus management may be relevant in later CKD stages but require individualized guidance from a clinician or renal dietitian — not general self-restriction.

What Clinicians May Discuss

When lifestyle measures alone are insufficient, clinicians may discuss additional interventions. This is an overview of what exists — not a recommendation to start, stop, or change any treatment.

• Blood pressure medications — certain classes (such as ACE inhibitors and ARBs) have additional kidney-protective properties beyond blood pressure lowering, particularly in people with proteinuria.
• SGLT2 inhibitors — originally developed for diabetes, these medications have shown kidney-protective effects in people with CKD regardless of diabetes status in recent clinical trials.
• Glycaemic management — in diabetic kidney disease, specific medication choices may be guided by kidney function level.
• Anaemia management — erythropoiesis-stimulating agents or iron supplementation when CKD-related anaemia develops.
• Mineral and bone disorder management — phosphate binders, vitamin D analogues, or other interventions for CKD-MBD.
• Dialysis and transplantation — renal replacement therapy options discussed when kidney function approaches or reaches stage G5.
• Multidisciplinary care — nephrologist, renal dietitian, diabetes educator, and cardiovascular team coordination.

Do not start, stop, or adjust any kidney-related medication without discussing it with your prescribing clinician.

Monitoring And Follow-Up

• Repeat eGFR and UACR — frequency depends on CKD stage and risk category (ranging from annually for low-risk to every 1–3 months for high-risk).
• Blood pressure monitoring — regular checks, potentially including home monitoring.
• Cardiovascular risk assessment — periodic review given the amplified risk in CKD.
• Electrolyte and mineral monitoring — potassium, calcium, phosphorus, and bicarbonate levels as CKD progresses.
• Haemoglobin/anaemia screening — particularly from stage G3 onwards.
• Medication review — dose adjustments for renally-cleared medications and avoidance of nephrotoxins.

Consumer Devices and Wearables: Important Limitations

• No consumer wearable or home device currently measures eGFR, creatinine, or albuminuria. Kidney function assessment requires laboratory blood and urine tests.
• Blood pressure monitors (validated cuff devices) can support hypertension management, which indirectly supports kidney health.
• Wearable hydration or "kidney health" claims from consumer devices are not clinically validated.
• Trend data from validated home blood pressure monitors can be useful context for clinician discussions.

When To Seek Urgent Help

CKD is usually managed as a chronic condition over time. However, seek immediate medical attention if you experience:

• Sudden significant decrease in urine output — producing very little or no urine over several hours may indicate acute kidney injury.
• Severe swelling (oedema) — rapid onset of swelling in legs, ankles, or around the eyes, especially with breathlessness.
• Difficulty breathing or chest tightness — may indicate fluid overload or pulmonary oedema. Call emergency services if severe.
• Confusion, drowsiness, or seizures — may indicate uraemia (toxic waste buildup) or severe electrolyte imbalance.
• Severe nausea and vomiting with inability to keep fluids down — risk of dehydration and acute kidney injury.
• Blood in urine (visible haematuria) — requires prompt evaluation.
• Very high blood pressure with headache, visual changes, or chest pain — hypertensive emergency. Call emergency services (911, 995, or your local number).
• Muscle weakness or heart palpitations — may indicate dangerous potassium levels (hyperkalaemia). Seek urgent evaluation.

Questions To Ask Your Doctor

• What is my current eGFR and UACR, and what do they mean in the context of my overall health?
• Do I have any risk factors that make kidney screening particularly important for me?
• How often should my kidney function be rechecked given my current results?
• Are any of my current medications potentially harmful to my kidneys?
• What blood pressure target is appropriate for me given my kidney function?
• Should I see a nephrologist (kidney specialist), or can my kidney health be managed in primary care for now?
• Are there dietary changes I should discuss with a renal dietitian?
• If my kidney function is declining, what are the options to slow progression?

Sources

• NIDDK/NIH. Chronic Kidney Disease (CKD). niddk.nih.gov
• CDC. Chronic Kidney Disease in the United States. cdc.gov/kidneydisease
• KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of CKD. Kidney Int Suppl. 2013;3(1):1–150.
• NKF. About Chronic Kidney Disease. kidney.org
• WHO. Kidney disease fact sheet. who.int
• Inker LA, et al. New Creatinine- and Cystatin C-Based Equations (CKD-EPI 2021). NEJM. 2021;385(19):1737–1749.
• Go AS, et al. Chronic Kidney Disease and Risks of Death, Cardiovascular Events, and Hospitalization. NEJM. 2004;351(13):1296–1305.
• NICE CG182. Chronic kidney disease in adults: assessment and management. nice.org.uk
• MedlinePlus. Chronic Kidney Disease. medlineplus.gov
• NHS. Chronic kidney disease overview. nhs.uk